Navigation Links
A Once-Daily Oral Drug for Chronic Obstructive Pulmonary Disease That Treats COPD-Related Inflammation Could Achieve Blockbuster Status
Date:2/27/2008

Although Physicians Report Satisfaction with GlaxoSmithKline's Advair and Boehringer Ingelheim/Pfizer's Spiriva, Significant Need Remains for a Novel Anti-Inflammatory Drug, According to a New Report from Decision Resources

WALTHAM, Mass., Feb. 27 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that surveyed physicians indicate that a novel, non- steroidal, anti-inflammatory agent for COPD that improves lung function could capture a significant share of the COPD market by replacing GlaxoSmithKline's Advair (also marketed as Seretide and Adoair).

The new report entitled Chronic Obstructive Pulmonary Disease: Opportunity Lies in Drugs That Address COPD-Related Inflammation finds that an oral, once- daily drug that treats COPD-related inflammation and improves lung function could achieve blockbuster status by 2016. Although an effective anti- inflammatory drug for COPD could replace Advair, it would likely be used in combination with Boehringer Ingelheim/Pfizer's Spiriva, according to the report. Spiriva's efficacy, safety, and convenience make it the current gold standard treatment for COPD but Advair's higher price, longer presence on the market and high prescribing by doctors made Advair the COPD market-share leader in 2006.

The report also finds that, following its approval in 2011 for the indication, Forest Laboratories/Almirall Prodesfarma's aclidinium will become the clinical gold standard for COPD by 2016. Aclidinium, a long-acting muscarinic antagonist (LAMA), will achieve gold standard status by 2016 because of its faster onset of action when compared to Spiriva.

"Because Spiriva is the first-to-market LAMA and has extensive clinical data and physician experience, we don't expect aclidinium to immediately achieve wide acceptance upon launch as the gold standard for COPD as physicians must first gain clinical experience with the drug," said Regina Jammen, analyst at Decision Resources. "We expect that clinical trials, specifically the UPLIFT trial, will provide results showing the benefits of the long-term use of Spiriva in COPD patients, and these results are likely to be generalized to other agents in the LAMA drug class, such as aclidinium."

About the Report

Chronic Obstructive Pulmonary Disease: Opportunity Lies in Drugs That Address COPD-Related Inflammation is a DecisionBase 2008 report from Decision Resources. DecisionBase 2008 combines market forecasts with clinical and commercial end points to assess market share projections in 35 indications. These outputs are driven by quantitative and qualitative primary research. DecisionBase 2008 provides detailed market share, patient share, and price- per-day projections for emerging drugs in development. The market share projections are based on prescriber surveys that compare physicians' expectations of a potential target product profile with an emerging product profile of the leading drugs in development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources, Inc. (http://www.decisionresources.com) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.

781-296-2563

emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Labopharms Once-Daily Tramadol Approved in South Korea and Australia
2. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
3. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
4. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
5. ISTA Pharmaceuticals Submits New Drug Application for Xibrom(TM) QD (once-daily)
6. Once-Daily Exjade(R) Shown to Remove Toxic Iron From the Heart and Liver, According to Data Presented at ASH
7. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
8. Labopharm appeals FDAs decision on once-daily tramadol
9. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
10. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
11. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... METTLER TOLEDO has launched its ... including white papers, guides, handbooks, case studies, magazines, webinars, videos, catalogs, brochures, datasheets, ... 9,000 documents, webinars and videos available online, visit the METTLER TOLEDO Expertise ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... 25th, when SevenPoint2 released the much-anticipated HydroFX for Water®. This first-of-its-kind water-soluble ... Featuring one of the world’s most powerful antioxidants, molecular hydrogen, HydroFX for ...
(Date:12/6/2016)... (PRWEB) , ... December 06, 2016 , ... Keeping Gift ... people choose gifts that are safe and age-appropriate for their recipients. This is the ... to reflect on the safety of items that would make good gifts for children. ...
(Date:12/6/2016)... Vancouver, B.C., Canada (PRWEB) , ... December 06, ... ... Consultants (STC) announce the availability of the newly updated International Audit Protocol Consortium ... world use IAPC EHS audit protocols to understand the scope of their EHS ...
(Date:12/6/2016)... ... 06, 2016 , ... The OSHA Training Center at ... Center headquartered in Northern California, has announced the addition of a Public Sector ... training to public sector employees. , “The primary goal of the Public Sector ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... 5, 2016 Research and Markets has ... (Instruments, Consumables), Application (Biomedical & Biochemical Research, Disease Diagnostics), End User ... to 2021" report to their offering. ... , , ... in 2021 from USD 574.8 Million in 2016, growing at a ...
(Date:12/5/2016)... 5, 2016 According to a new report published by ... - Global Opportunity Analysis and Industry Forecast, 2014 - 2022", the global surgical ... $5,255 million by 2022, growing at a CAGR of 6.4% from 2016 to ... share. Continue Reading ... ...
(Date:12/5/2016)... --  TrainerMD , the first HIPAA compliant software collaboration platform for ... Styku . Styku, a California -based ... users world-class, real-time 3D body scanning and analysis. Together with its ... hear and feel their health like never before. ... , , ...
Breaking Medicine Technology: